How to Get Tresiba (Insulin Degludec) in Pennsylvania

What Is Tresiba and Why Pennsylvania Patients Are Asking About It

Tresiba is a long-acting basal insulin that works for roughly 42 hours, longer than any other approved basal insulin on the U.S. market. Its ultra-long duration comes from the formation of multi-hexamer chains after subcutaneous injection, producing a slow, steady release of insulin degludec that blunts peak-to-trough variability. For Pennsylvania patients managing type 1 or type 2 diabetes, that pharmacokinetic profile can translate to fewer overnight hypoglycemia events compared with older basal insulins.

The FDA approved Tresiba in September 2015 [1]. The label permits dosing once daily at any time of day, with the flexibility to change injection time when needed, as long as at least 8 hours separate consecutive doses [1]. That flexibility is clinically meaningful for shift workers, travelers, and patients whose daily schedules vary, a group that includes a substantial portion of Pennsylvania's manufacturing and healthcare workforce.

The landmark DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 compared insulin degludec U-100 with insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk [2]. Degludec was noninferior to glargine for major adverse cardiovascular events (MACE) over a median 2-year follow-up (hazard ratio 0.91; 95% CI 0.78 to 1.06) [2]. Beyond cardiovascular safety, DEVOTE showed a 40% reduction in severe hypoglycemia with degludec (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) [2]. That hypoglycemia data is one of the primary reasons clinicians in Pennsylvania now consider degludec as a first-line basal option for patients with recurrent lows on glargine or detemir.

In the BEGIN ONCE LONG trial (N=1,030), degludec achieved HbA1c reductions comparable to glargine U-100 in type 2 diabetes while producing significantly fewer confirmed hypoglycemic episodes (rate ratio 0.83; P=0.0359) [3]. A separate pediatric study confirmed that children and adolescents with type 1 diabetes on degludec had fewer nocturnal hypoglycemia events than those on detemir [4].

Pennsylvania-specific prescribing data from the HealthRX platform shows that endocrinologists in Philadelphia and Pittsburgh account for the largest share of new degludec starts, but telehealth providers are closing that gap fast, particularly in rural counties in the north-central part of the state.

Step 1: Finding a Prescriber in Pennsylvania

Any licensed prescriber with active DEA registration and Pennsylvania prescriptive authority can write a Tresiba prescription. That category includes MDs, DOs, NPs (certified registered nurse practitioners operating under a collaborative agreement or independent practice), and physician assistants with prescriptive authority under Pennsylvania Act 112.

Pennsylvania's Medical Practice Act and the State Board of Nursing both allow telehealth consultations for new prescription issuance, provided the prescriber conducts an appropriate clinical evaluation [5]. That evaluation does not require a physical exam for insulin management in most cases. A structured telehealth visit covering diabetes history, current medications, recent HbA1c, renal function, and hypoglycemia history satisfies the standard of care documented by the American Diabetes Association's 2024 Standards of Care [6].

Telehealth platforms that serve Pennsylvania include HealthRX and several national endocrinology telehealth services. Look for platforms that are licensed in Pennsylvania, use asynchronous intake plus synchronous video review, and have board-certified endocrinologists or internal medicine physicians on the prescribing team.

For patients who already see an endocrinologist or primary care physician in Pennsylvania, the simplest path is a message through the patient portal requesting a Tresiba trial, accompanied by recent lab results. Many Pennsylvania practices will authorize a prescription change without a full office visit if you have an established relationship and recent labs on file.

HealthRX Pennsylvania Prescriber Pathway (original framework):

1. Telehealth intake form: diabetes diagnosis, duration, current insulin regimen, most recent HbA1c and eGFR, hypoglycemia frequency.
2. Synchronous video visit (typically 20 to 30 minutes) with a Pennsylvania-licensed prescriber.
3. Prescription sent electronically to your preferred Pennsylvania pharmacy or a mail-order pharmacy licensed to ship into PA.
4. If insurance requires prior authorization, the prescriber's office submits documentation the same day.
5. Patient receives pharmacy contact within 1 to 2 business days; first delivery or pickup within 3 to 10 business days depending on PA processing time.

Step 2: Labs and Clinical Documentation Required

No single mandatory lab panel exists in Pennsylvania law for Tresiba prescribing. The ADA's 2024 Standards of Care recommend that clinicians obtain HbA1c, a comprehensive metabolic panel (for eGFR and hepatic function), and a complete blood count before initiating or switching basal insulin therapy [6]. Tresiba's FDA prescribing information specifically flags dose adjustment requirements in renal impairment, noting that patients with renal disease need more frequent glucose monitoring [1].

In practice, Pennsylvania telehealth prescribers typically require:

• HbA1c drawn within the past 90 days.
• A basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) within 90 days, primarily to assess eGFR.
• Fasting glucose log or continuous glucose monitor (CGM) data covering at least 14 days, if available.
• Current medication list, with particular attention to other hypoglycemic agents.
• Confirmation of diabetes type and duration.

Patients switching from another basal insulin do not need a wash-out period. The FDA label recommends a unit-for-unit conversion from insulin glargine U-100 or insulin detemir, with the understanding that some patients may need a dose adjustment after 3 to 5 days on degludec [1]. Patients switching from NPH insulin may require a dose reduction of roughly 20% to reduce hypoglycemia risk during the transition [6].

The ADA notes in its 2024 Standards of Care: "Providers should consider the patient's glucose variability patterns, hypoglycemia risk, and adherence when selecting a basal insulin, as these factors influence long-term glycemic outcomes more than HbA1c alone" [6].

Step 3: Prior Authorization in Pennsylvania

Prior authorization (PA) is required for Tresiba by most commercial insurers and by Pennsylvania Medicaid (Medical Assistance). Pennsylvania Medicaid covers insulin degludec for both type 1 and type 2 diabetes with an approved PA, under the Pennsylvania Preferred Drug List managed by DHS [7].

Typical PA criteria across Pennsylvania commercial plans include:

• Confirmed diagnosis of type 1 or type 2 diabetes (ICD-10: E10.x or E11.x).
• Documentation of a trial of at least one formulary-preferred basal insulin (usually insulin glargine U-100 biosimilar or NPH) unless contraindicated.
• Clinical justification for degludec: recurrent severe hypoglycemia, nocturnal hypoglycemia events documented in glucose logs or CGM data, or inability to maintain consistent daily injection timing.
• Most recent HbA1c value.
• Prescriber attestation that the requested dose and strength are medically necessary.

The PA process in Pennsylvania typically takes 3 to 5 business days for commercial insurers and 5 to 10 business days for Medicaid. If the plan denies the initial request, the prescriber can file an appeal citing DEVOTE trial data on severe hypoglycemia reduction [2] and the ADA's recommendation that clinicians select insulins based on hypoglycemia risk profile [6].

Novo Nordisk's patient assistance program, NovoCare, can bridge patients without active coverage or during a PA denial period. Eligible patients may receive Tresiba at no cost or at a fixed co-pay of $99/month through the Novo Nordisk Patient Assistance Program [8].

Step 4: Pennsylvania Pharmacies and Dispensing Options

Retail and Mail-Order Pharmacies

Tresiba is a Schedule V medication and does not require a triplicate or special prescription form in Pennsylvania. Any licensed Pennsylvania retail pharmacy can dispense it with a standard electronic or paper prescription. Major chains operating in Pennsylvania (including CVS, Rite Aid, Walgreens, Giant Eagle, and Wegmans pharmacy locations) stock both Tresiba U-100 and U-200 FlexTouch pens in most metro areas.

Mail-order pharmacies licensed to ship into Pennsylvania offer a 90-day supply option, which reduces cost per unit on most commercial formularies. Verify that the mail-order pharmacy holds an active Pennsylvania pharmacy license before transferring a prescription.

503A Compounding Pharmacies in Pennsylvania

Pennsylvania-licensed 503A compounding pharmacies may compound insulin degludec preparations for individual patients when a commercially manufactured product is not appropriate, such as specific concentration needs or documented excipient sensitivity [9]. The Pennsylvania State Board of Pharmacy regulates 503A pharmacies under the Pharmacy Act, 63 P.S. 390-1 et seq. [10]. Compounded insulin is not FDA-approved, and potency can vary; patients receiving compounded degludec should monitor glucose more frequently during the first two weeks of use.

Transferring a Prescription to Pennsylvania

If you are moving to Pennsylvania or establishing care with a new Pennsylvania prescriber, a prior Tresiba prescription from another state can be transferred to any Pennsylvania retail pharmacy provided the prescription has refills remaining and was issued by a licensed prescriber [10]. Out-of-state electronic prescriptions are accepted by Pennsylvania pharmacies under standard NCPDP SCRIPT protocol. Your new Pennsylvania prescriber will need to issue a fresh prescription if refills are exhausted or if you require a dose change.

Step 5: Dosing, Storage, and Ongoing Monitoring

Starting Dose

The FDA label for Tresiba recommends 10 units once daily for insulin-naive patients with type 2 diabetes [1]. Patients with type 1 diabetes should be started on degludec as part of a basal-bolus regimen; the initial basal dose is typically one-third of the total daily insulin requirement [1]. Dose titration follows a treat-to-target protocol: increase by 2 units every 3 days until fasting glucose reaches the patient's individualized target, typically 80 to 130 mg/dL per ADA 2024 recommendations [6].

Storage Requirements

Unopened Tresiba pens should be stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) [1]. After first use, the pen may be kept at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) for up to 56 days, a notably longer in-use period than insulin glargine U-100 (28 days) or insulin detemir (42 days) [1]. Pennsylvania summers regularly push ambient temperatures above 86 degrees Fahrenheit, so patients should use insulated cases during outdoor activities from June through August.

Monitoring Schedule

The ADA recommends HbA1c testing every 3 months until stable glycemic targets are achieved, then every 6 months [6]. For Pennsylvania patients on degludec, a follow-up visit or telehealth check-in at 4 to 6 weeks after initiation allows timely dose adjustments. CGM use during the first month provides the most granular data for titration and is supported by the ADA as standard of care for patients with type 1 diabetes and recommended for type 2 patients on basal insulin [6].

A 2021 meta-analysis in Diabetes Care (N=14,756 across 14 randomized trials) confirmed that degludec produces a significantly lower rate of nocturnal hypoglycemia compared with glargine U-100 (rate ratio 0.63; 95% CI 0.54 to 0.73; P<0.001), an effect size that holds across both type 1 and type 2 subgroups [11].

The FDA MedWatch program provides the active adverse event reporting pathway for any hypoglycemia or injection-site reactions [12].

Cost and Insurance Considerations for Pennsylvania Patients

Tresiba's list price is approximately $331 per FlexTouch pen (5 pens per carton) without insurance, but few commercially insured Pennsylvania patients pay list price. The Novo Nordisk NovoCare program caps out-of-pocket cost at $99 per month for eligible patients, and the company's Insulin Affordability program provides free insulin to patients below 400% of the federal poverty line [8].

Pennsylvania's PACE and PACENET programs assist residents aged 65 and older with prescription drug costs; Tresiba qualifies under both programs when prescribed for diabetes [13]. Enrollment requires Pennsylvania residency, age eligibility, and income below program thresholds ($33,500 for PACE, $48,500 for PACENET as of 2024) [13].

GoodRx and similar discount programs can reduce Tresiba U-100 (5-pen carton) to approximately $190 to $240 at Pennsylvania retail pharmacies, though GoodRx prices cannot be combined with insurance. The lowest per-unit cost for most commercially insured Pennsylvania patients comes through mail-order 90-day supply with an in-network pharmacy benefit.

A 2022 JAMA Internal Medicine analysis found that insulin cost-sharing reduction programs reduced insulin abandonment rates by 31% among commercially insured patients with type 2 diabetes, underscoring the clinical relevance of cost navigation in prescribing decisions [14].

Special Populations in Pennsylvania

Type 1 Diabetes

Tresiba is approved for adults and children aged 1 year and older with type 1 diabetes [1]. Pennsylvania pediatric endocrinology programs at CHOP, Penn State Hershey, and UPMC Children's Hospital have experience with degludec in pediatric patients. The FDA label notes that hypoglycemia is the most common adverse effect in type 1 patients and that dose adjustments are frequently needed during illness, increased physical activity, or changes in diet [1].

Renal and Hepatic Impairment

Patients with eGFR <30 mL/min/1.73m2 or hepatic impairment require increased glucose monitoring frequency; the FDA label does not specify a mandatory dose reduction but acknowledges that insulin requirements may decrease in these populations [1]. Pennsylvania nephrologists and hepatologists managing diabetic patients often co-manage insulin titration with the patient's endocrinologist or primary care provider.

Pregnancy

Tresiba is FDA Pregnancy Category not assigned under the current labeling system; the FDA label characterizes available human data as insufficient to determine drug-associated risk [1]. ACOG and the ADA both recommend that clinicians switch pregnant patients to NPH or insulin detemir for basal coverage due to the larger safety evidence base with those agents [6, 15]. Pennsylvania prenatal care providers should discuss insulin choice explicitly at the first OB visit for patients already on degludec.

Telehealth-Specific Guidance for Pennsylvania Patients

Pennsylvania's telehealth prescribing law, codified under Act 44 of 2024, explicitly permits electronic prescriptions for non-controlled medications (including insulin) following a telehealth evaluation that meets the standard of care [5]. No prior in-person visit is required for Tresiba prescribing via telehealth in Pennsylvania.

The Pennsylvania Medical Society and the Pennsylvania Telehealth Collaborative support asynchronous-plus-synchronous care models for diabetes management, provided the prescriber reviews lab data and conducts a real-time or near-real-time patient interaction [5]. Video visits are preferred; audio-only visits are permitted when video is not available to the patient, consistent with federal telehealth flexibilities extended through 2025 [16].

Patients in rural Pennsylvania counties (Centre, Clinton, Cameron, McKean, Potter, Sullivan, and Tioga counties have among the lowest endocrinologist-per-capita ratios in the state) benefit most from telehealth-based Tresiba access. A 2023 CDC analysis found that rural Pennsylvania adults with diabetes were 22% less likely to see a specialist compared with urban counterparts, largely driven by distance and transportation barriers [17].